| Literature DB >> 27910068 |
Nuria Eritja1,2, Andree Yeramian1,2, Bo-Juen Chen3, David Llobet-Navas4, Eugenia Ortega1, Eva Colas1,2,5, Miguel Abal2,6, Xavier Dolcet1,2, Jaume Reventos2,5, Xavier Matias-Guiu7,8.
Abstract
Endometrial cancer (EC) is the most common gynecologic malignancy in the western world with more than 280,000 cases per year worldwide. Prognosis for EC at early stages, when primary surgical resection is the most common initial treatment, is excellent. Five-year survival rate is around 70 %.Several molecular alterations have been described in the different types of EC. They occur in genes involved in important signaling pathways. In this chapter, we will review the most relevant altered pathways in EC, including PI3K/AKT/mTOR, RAS-RAF-MEK-ERK, Tyrosine kinase, WNT/β-Catenin, cell cycle, and TGF-β signaling pathways. At the end of the chapter, the most significant clinical trials will be briefly discussed.This information is important to identify specific targets for therapy.Entities:
Keywords: Endometrial cancer; PI3K pathology; Signaling pathway; Target therapies
Mesh：
Substances：
Year: 2017 PMID： 27910068 DOI： 10.1007/978-3-319-43139-0_6
Source DB: PubMed Journal: Adv Exp Med Biol ISSN： 0065-2598 Impact factor: 2.622